1
|
Bui H, Adamson PC, Klausner JD, Le GM, Gorbach PM. Doxycycline prophylaxis for sexually transmitted infection prevention in Vietnam: Awareness, attitudes, and willingness to use among men who have sex with men using HIV-PrEP. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2024:2024.12.02.24318296. [PMID: 39677489 PMCID: PMC11643152 DOI: 10.1101/2024.12.02.24318296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/17/2024]
Abstract
Objectives Doxycycline prophylaxis shows promise for sexually transmitted infection (STI) prevention, but data primarily come from high-income countries. This study assessed awareness, willingness and factors associated with willingness to use doxycycline for STI prevention among men who have sex with men (MSM) using HIV-PrEP in Vietnam. Methods Between January 25 and February 4, 2024, a cross-sectional study recruited males aged ≥18 years who reported sex with men in the past 12 months from 11 PrEP clinics in Hanoi and Ho Chi Minh City. Self -administered surveys were conducted, and multivariable logistic regression was applied to identify factors associated with willingness to use doxyPEP/PrEP. Results Among 350 participants (45.7% Hanoi, 54.3% Ho Chi Minh City), the median age was 25 (interquartile range [IQR]: 21-30), and 10.6% self-reported an STI diagnosis in the past 12 months. In the previous 6 months, the median number of sex partners was 2 (IQR: 1-4), 53.1% reported condomless anal sex. Awareness of doxycycline was low (20.2%; 65/322), however, 75.4% (264/350) expressed willingness to use it, with 63.6% (168/264) preferring doxyPrEP. Participants who disclosed HIV-PrEP use to all sex partners (adjusted odds ratio [aOR]: 4.17; 95% confidence interval [95%CI] 1.84, 9.46), and those with higher perceived STI risk (aOR: 1.12; 95% CI 1.03, 1.22) were more likely to report willingness to use doxycycline prophylaxis. Concerns about daily medication (aOR: 0.43; 95% CI 0.24, 0.81) and fear of judgement from peers (aOR: 0.41; 95% CI: 0.21, 0.81) were associated with lower willingness. Conclusions Knowledge of doxyPEP/PrEP among MSM on HIV-PrEP in Vietnam was low. However, most expressed willingness to use doxycycline prophylaxis, with two-thirds preferring doxyPrEP. Findings highlight the need to disseminate information on doxyPEP/PrEP for STI prevention strategy, evaluating the usage and comparative effectiveness of doxyPEP and doxyPrEP to guide implementation efforts in Vietnam. 1 What is already known on this topic Men who have sex with men (MSM) experience a disproportionate burden of HIV and bacterial sexually transmitted infections (STIs) worldwide, including in Vietnam. Despite the successful expansion of HIV Pre-Exposure Prophylaxis (PrEP) programs in Vietnam, bacterial STI rates remain persistently high among PrEP users, highlighting gaps in prevention efforts. Evidence from high-income countries (HICs) suggests that doxycycline prophylaxis can significantly reduce the incidence of bacterial STIs such as syphilis and chlamydia. However, little is known about the awareness, acceptability, and feasibility of doxycycline prophylaxis in Vietnam and other low-and middle-income countries (LMICs). 2 What this study adds This study is the first to assess awareness, attitudes, and willingness to use doxycycline prophylaxis for STI prevention among MSM in Vietnam, a LMIC setting. Despite low prior awareness, the study found high willingness (75.4%) to use doxycycline, with most participants preferring daily doxyPrEP over doxyPEP. It also identified critical facilitators, such as perceived high STI risk and disclosure of HIV-PrEP use to sex partners, as well as barriers, including stigma, cost, and concerns about daily medication. These findings provide insights into the feasibility of introducing doxycycline prophylaxis in Vietnam, distinguishing it from contexts in HICs where different preferences and barriers may exist. 3 How this study might affect research practice or policy This study provides a foundation for further research on doxycycline prophylaxis in LMICs, emphasizing the need to evaluate its real-world effectiveness and implementation in settings with high AMR prevalence. Policymakers can use these findings to develop tailored guidelines and subsidies for doxycycline prophylaxis in Vietnam, ensuring affordability and accessibility.
Collapse
|
2
|
Künzler-Heule P, Schmidt AJ, Fierz K, Battegay M, Engberg S, Kouyos RD, Nöstlinger C, Stöckle M, Béguelin C, Delaloye J, Schmid P, Rougemont M, Braun DL, Fehr JS, Nicca D. Exploring group differences in the response to a sexual risk reduction intervention to prevent hepatitis C virus reinfection in HIV-infected MSM: a mixed-methods study. AIDS Care 2024; 36:442-451. [PMID: 37182220 DOI: 10.1080/09540121.2023.2208318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Accepted: 04/21/2023] [Indexed: 05/16/2023]
Abstract
To prevent hepatitis C virus (HCV) reinfection, within the Swiss HCVree Trial, a preventive risk reduction intervention was implemented alongside curative treatment. Formative qualitative research identified three response patterns to the intervention. This mixed-methods study's aim was to cross-validate group differences in (a) the content of sexual risk reduction goals set during intervention and (b) the extent of their behavioural change in condomless anal intercourse with non-steady partners (nsCAI), sexualised and intravenous drug use at start and six-month post-intervention. Qualitative thematic analysis was used to summarise goal setting domains. Quantitative descriptive analysis was used to evaluate group differences based on assumptions of the group descriptions. Results largely confirmed assumptions on inter-group response differences in goal setting and behaviour: as expected group 1 Avoid risks showed the lowest HCV risk profile with changes in nsCAI. Group 2 Minimize-risks and Group 3 Accept-risks showed unchanged nsCAI. Group 3 had the highest HCV risk profile. Differences in their goal preferences (1: condom use; 2 reduction blood exposure; 3 safer dating) highlight diversity in attitudes to behavioural change. Our results improve understanding of variability in intervention responses such as changes in attitudes and behaviour. This provides evidence for intervention tailoring and outcome measurement.
Collapse
Affiliation(s)
- Patrizia Künzler-Heule
- Nursing Science, Department Public Health, Medical Faculty, University of Basel, Basel, Switzerland
- Department of Gastroenterology/Hepatology and Department of Nursing Development, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Axel J Schmidt
- Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
- Sigma Research, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Katharina Fierz
- Zurich University of Applied Sciences (ZUAS), Winterthur, Switzerland
| | - Manuel Battegay
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
- Medical Faculty, University of Basel, Basel, Switzerland
| | - Sandra Engberg
- Nursing Science, Department Public Health, Medical Faculty, University of Basel, Basel, Switzerland
- University of Pittsburgh, School of Nursing, Pittsburgh, PA, USA
| | - Roger D Kouyos
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
| | | | - Marcel Stöckle
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
- Medical Faculty, University of Basel, Basel, Switzerland
| | - Charles Béguelin
- Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Switzerland
| | - Julie Delaloye
- Intensive Care Unit, Department of Intensive Care Medicine, University of Lausanne and University Hospital Center, Lausanne, Switzerland
| | - Patrick Schmid
- Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Mathieu Rougemont
- Primary Care Medicine Unit, University Hospital of Geneva, Geneva, Switzerland
| | - Dominique L Braun
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
- Institute of Medical Virology, University of Zurich, Zurich, Switzerland
| | - Jan S Fehr
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
- Department of Public & Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
| | - Dunja Nicca
- Nursing Science, Department Public Health, Medical Faculty, University of Basel, Basel, Switzerland
- Department of Public & Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
| |
Collapse
|
3
|
Prinsenberg T, Schinkel J, Zantkuijl P, Davidovich U, Prins M, van der Valk M. Internet-guided HCV-RNA testing: A promising tool to achieve hepatitis C micro-elimination among men who have sex with men. J Viral Hepat 2022; 29:677-684. [PMID: 35583928 PMCID: PMC9545250 DOI: 10.1111/jvh.13706] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2022] [Accepted: 04/11/2022] [Indexed: 12/09/2022]
Abstract
In the Netherlands, hepatitis C virus (HCV) transmission occurs primarily in men who have sex with men (MSM). By early diagnosis and immediate treatment of acute HCV infections, HCV micro-elimination in MSM is within reach. In cooperation with the community affected, we developed an online HCV-RNA home-based self-sampling test service. This service combined online HCV self-risk assessment with the possibility to test anonymously for HCV-RNA. The service was available in the Netherlands from February 2018 till December 2020 and was promoted online on various dating sites and offline by community volunteers. Using website user data, test results and an online post-test user survey, we evaluated the service and user experiences. The website page with information about testing was visited by 3401 unique users, of whom 2250 used the HCV-risk assessment tool, 152 individuals purchased 194 HCV-RNA tests, and 104 tests were used, of which 101 gave a conclusive result. The target population of MSM at risk was successfully reached with 44.1% of users receiving the advice to test. The test service had a satisfactory uptake (6.8%, 152/2250), a very high HCV-RNA positivity rate (10.9%, 11/101) and was considered acceptable and easy to use by most MSM. We demonstrate that an HCV-RNA home-based self-sampling test service is successful in diagnosing HCV infections among MSM. This service could be a valuable addition to existing sexual healthcare services as it may reach men who are otherwise not tested.
Collapse
Affiliation(s)
- Tamara Prinsenberg
- Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam UMCUniversity of AmsterdamAmsterdamThe Netherlands,Department of Infectious Diseases Research and PreventionPublic Health Service of AmsterdamAmsterdamThe Netherlands
| | - Janke Schinkel
- Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam UMCUniversity of AmsterdamAmsterdamThe Netherlands,Department of Medical Microbiology, Section of Clinical Virology, Amsterdam UMCUniversity of AmsterdamAmsterdamThe Netherlands
| | | | - Udi Davidovich
- Department of Infectious Diseases Research and PreventionPublic Health Service of AmsterdamAmsterdamThe Netherlands,Department of Social PsychologyUniversity of AmsterdamAmsterdamThe Netherlands
| | - Maria Prins
- Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam UMCUniversity of AmsterdamAmsterdamThe Netherlands,Department of Infectious Diseases Research and PreventionPublic Health Service of AmsterdamAmsterdamThe Netherlands
| | - Marc van der Valk
- Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam UMCUniversity of AmsterdamAmsterdamThe Netherlands,HIV Monitoring FoundationAmsterdamThe Netherlands
| |
Collapse
|
4
|
Prinsenberg T, Illidge J, Zantkuijl P, Bedert M, Prins M, van der Valk M, Davidovich U. Usability, acceptability, and self-reported impact of an innovative hepatitis C risk reduction intervention for men have sex with men: A mixed methods study. PLoS One 2022; 17:e0263654. [PMID: 35180246 PMCID: PMC8856530 DOI: 10.1371/journal.pone.0263654] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 01/24/2022] [Indexed: 11/21/2022] Open
Abstract
Hepatitis C virus (HCV) elimination among men who have sex with men (MSM) is unlikely to be feasible without effective behavioural interventions. We developed a multilevel intervention to reduce HCV transmission among MSM in Amsterdam. The intervention includes a toolbox to facilitate risk reduction among MSM and support health care professionals in risk reduction counselling. To assess the use of the toolbox and its impact on behavior, we conducted a mixed-methods study. We collected data through online questionnaires (n = 49), and in-depth interviews with MSM at risk of HCV (n = 15) and health care professionals (n = 7). We found that the toolbox has been well received by MSM, increased awareness of HCV risks and has facilitated preventive behaviours and risk-reduction communication with peers. Professionals reported the toolbox to be a useful aid for discussions about HCV risk and risk reduction strategies with their clients.
Collapse
Affiliation(s)
- Tamara Prinsenberg
- Department of Infectious Diseases Research and Prevention, Public Health Service of Amsterdam, Amsterdam, The Netherlands
- Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Joël Illidge
- Department of Infectious Diseases Research and Prevention, Public Health Service of Amsterdam, Amsterdam, The Netherlands
| | | | - Maarten Bedert
- Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Maria Prins
- Department of Infectious Diseases Research and Prevention, Public Health Service of Amsterdam, Amsterdam, The Netherlands
- Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Marc van der Valk
- Department of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
- Stichting HIV Monitoring, Amsterdam, The Netherlands
| | - Udi Davidovich
- Department of Infectious Diseases Research and Prevention, Public Health Service of Amsterdam, Amsterdam, The Netherlands
- Department of Social Psychology, University of Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|
5
|
Künzler-Heule P, Fierz K, Schmidt AJ, Rasi M, Bogdanovic J, Kocher A, Engberg S, Battegay M, Nöstlinger C, Lehner A, Kouyos R, Schmid P, Braun DL, Fehr J, Nicca D. Response to a sexual risk reduction intervention provided in combination with hepatitis C treatment by HIV/HCV co-infected men who have sex with men: a reflexive thematic analysis. BMC Infect Dis 2021; 21:319. [PMID: 33823783 PMCID: PMC8022541 DOI: 10.1186/s12879-021-06003-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Accepted: 03/16/2021] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Hepatitis C virus reinfections in HIV-positive men-who-have-sex-with-men (MSM) challenge the effectiveness of antiviral treatment. To fight this problem, an adapted sexual risk reduction intervention was implemented within a hepatitis C treatment trial. Following this, the current study had two aims and describes 1) how the program was received by participants; and 2) their responses to the program regarding sexual risk taking. Based on the participants' input, we hoped to judge the intervention's potential for scale-up. METHODS Seventeen participants who received the sexual risk reduction intervention in addition to hepatitis C treatment were recruited for semi-structured interviews six to 12 months post-intervention. We evaluated the responses via reflexive thematic analysis and applied the concept of sense-making. RESULTS Giving hepatitis C a place and living without it again illustrates how participants received the program and how their experiences were altered by the impact of sense-making. Based on their responses, we allocated participants to three groups: 1. Avoid risks: get rid of hepatitis C for life. For these men, hepatitis C remained a life-threatening disease: they actively modified their risk behavior and felt supported by the intervention in maintaining their behavioral changes. 2. Minimize risks: live as long as possible without hepatitis C. In contrast to group 1, these men saw hepatitis C as a manageable disease. The intervention facilitated reflection on risks and how to develop behavioral changes that suited them individually. 3. Accept risks; live with the risk of hepatitis C. These men perceived behavioral changes as much more difficult than "easy" medical treatment. They expected to either undergo repeated rounds of treatment or stay HCV re-infected. CONCLUSION These results illustrate the diversity of men's responses and their decisions regarding sexual risk behavior after participating in a combination of antiviral treatment and a sexual risk reduction intervention. Two major aspects were identified: 1) Teachable moments, particularly at the time of diagnosis/treatment, could offer an opportunity to develop openness for behavioral change; 2) adapting sexual risk reduction interventions to sense-making patterns could help to improve its effectiveness. Support for reducing infection risk and raising awareness of preventative measures are additional benefits. TRIAL REGISTRATION Clinical Trial Number: NCT02785666 , 30.05.2016.
Collapse
Affiliation(s)
- Patrizia Künzler-Heule
- Nursing Science, Department Public Health, Medical Faculty, University of Basel, Basel, Switzerland.,Department of Gastroenterology/Hepatology and Department of Nursing, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Katharina Fierz
- Zurich University of Applied Sciences (ZUAS), Winterthur, Switzerland
| | - Axel Jeremias Schmidt
- Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.,Sigma Research, London School of Hygiene and Tropical Medicine, London, UK
| | - Manuela Rasi
- Department of Public & Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
| | - Jasmina Bogdanovic
- Nursing Science, Department Public Health, Medical Faculty, University of Basel, Basel, Switzerland
| | - Agnes Kocher
- Nursing Science, Department Public Health, Medical Faculty, University of Basel, Basel, Switzerland
| | - Sandra Engberg
- Nursing Science, Department Public Health, Medical Faculty, University of Basel, Basel, Switzerland.,School of Nursing, University of Pittsburgh, Pittsburgh, USA
| | - Manuel Battegay
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.,Medical Faculty, University of Basel, Basel, Switzerland
| | | | | | - Roger Kouyos
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
| | - Patrick Schmid
- Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Dominique Laurent Braun
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.,Institute of Medical Virology, University of Zurich, Zurich, Switzerland
| | - Jan Fehr
- Department of Public & Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.,Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
| | - Dunja Nicca
- Nursing Science, Department Public Health, Medical Faculty, University of Basel, Basel, Switzerland. .,Department of Public & Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
| |
Collapse
|